BioForce Nanosciences Inc., National Cancer Institute, FDA deal

BioForce partnered with the NCI and FDA to develop a proteomics-based screening assay for pre-malignant cancers. The deal combines BioForce's NanoArray technology with reverse-phase protein microarra...